Research Brief
TB-500: Mechanism of Action
Mecanismo de Acao
Alvo Primario: Sequestro de G-Actina
O alvo molecular fundamental do TB-500 e a actina globular monomerica (G-actina). O motivo LKKTETQ liga-se a G-actina em um complexo estequiometrico 1:1, sequestrando a actina monomerica e prevenindo sua polimerizacao descontrolada em actina filamentosa (F-actina).[6] Ao regular a polimerizacao de actina, o TB-500 modula a organizacao do citoesqueleto — pre-requisito para a motilidade e migracao celular essenciais para o reparo tecidual.[9]
Interacao com ATP Sintase
A Tβ4 (e potencialmente seus fragmentos ativos) interage com a F1-F0 ATP sintase na superficie de celulas endoteliais, ligando-se a subunidade beta com uma constante de dissociacao (KD) de aproximadamente 12 nM. Essa interacao aumenta os niveis de ATP na superficie celular, necessario para a sinalizacao de receptores purinergicos envolvidos na migracao celular.[10]
Via ILK-PINCH-Akt (Sobrevivencia Celular)
O TB-500 forma um complexo funcional com a Quinase Ligada a Integrina (ILK) e PINCH (Particularmente Interesting New Cys-His protein). Este complexo leva a fosforilacao e ativacao da Akt (Proteina Quinase B), especificamente Akt2 em celulas endoteliais, promovendo sobrevivencia celular e protecao de cardiomiocitos apos lesao isquemica.[11][12]
Via NF-κB (Anti-inflamatoria)
O TB-500 modula a inflamacao interrompendo a via de transduc
ao de sinal do NF-κB. Ele bloqueia a fosforilacao e a translocacao nuclear da subunidade RelA/p65, suprimindo a transcricao de citocinas pro-inflamatorias IL-8, IL-1β e TNF-α.[13][14]
Suprarregulacao de Metaloproteinases de Matriz (MMP)
O peptideo aumenta a producao de Metaloproteinases de Matriz (MMP-2 e MMP-9), enzimas necessarias para degradar a membrana basal e facilitar a migracao celular durante a angiogenese e o reparo de feridas.[15]
Suprarregulacao de Enzimas Antioxidantes
O TB-500 suprarregula a superoxido dismutase de manganes (Mn-SOD), SOD de cobre/zinco e catalase, fornecendo citoprotecao contra o estresse oxidativo.[16]
TB-500 vs. Timosina Beta-4 de Comprimento Total
Uma distincao critica: as propriedades antifibroticas da Tβ4 sao em grande parte atribuidas ao tetrapeptideo N-terminal Ac-SDKP (aminoacidos 1–4), que nao esta presente no TB-500. O Ac-SDKP inibe a proliferacao de celulas-tronco hematopoieticas e reduz a fibrose interferindo na sinalizacao TGF-β. Portanto, o TB-500 mantem as propriedades de ligacao a actina e migratorias, mas pode carecer da sinalizacao antifibrotica especifica da proteina de comprimento total.[7]
Alem disso, pesquisas recentes (Rahaman et al., 2024) sugerem que o metabolito do TB-500 Ac-LKKTE pode ser o principal impulsionador da cicatrizacao de feridas, e nao o peptideo parental em si.[17]
Referencias
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization do(a) N-terminal acetylated 17-23 fragment of thymosin beta 4 identificado(a) in TB-500. Drug Testing and Analysis. 2012;4(9):733-738.
- Delcourt V, Garcia P, Chabot B, Bailly-Chouriberry L. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis. 2022;14(12):1963-1969.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- U.S. Food and Drug Administration. Certain Substancia Farmaceutica a Granels for Use in Compounding que May Present Significant Safety Risks. FDA.gov. Updated July 8, 2025.
- World Anti-Doping Agency. The 2025 Lista de Substancias Proibidas. WADA. January 1, 2025.
- Xing Y, Ye Y, Zuo H, Li Y. Progress no(a) Function and Application of Thymosin β4. Frontiers in Endocrinology. 2021;12:767785.
- Bock-Marquette I, Maar K, Maar S, et al. Thymosin beta-4 denotes novo(a) directions towards developing prosperous anti-envelhecimento regenerative therapies. International Immunopharmacology. 2023;116:109741.
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin β4 e um(a) synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db camundongos diabeticos e em camundongos idosos. Wound Repair and Regeneration. 2003;11(1):19-24.
- Belsky JB, Rivers EP, Filbin MR, Lee PJ, Morris DC. Thymosin beta 4 regulacao of actin in sepse. Expert Opinion on Biological Therapy. 2018;18(sup1):193-197.
- Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 e um(a) essencial paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotecao. Circulation. 2008;117(17):2232-2240.
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 ativa integrin-linked kinase and promove cardiac migracao celular, survival and cardiac repair. Nature. 2004;432(7016):466-472.
- Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induz adult epicardial progenitor mobilization and neovascularizacao. Nature. 2007;445(7124):177-182.
- Sosne G, Kleinman HK. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Investigative Ophthalmology & Visual Science. 2015;56(9):5110-5117.
- Reyes-Gordillo K, Shah R, Popratiloff A, et al. Thymosin-β4 (Tβ4) Blunts PDGF-Dependent Phosphorylation and Binding of AKT to Actin in Hepatic Stellate Cells. American Journal of Pathology. 2011;178(5):2100-2108.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta 4 acelera cicatrizacao de feridas. Journal of Investigative Dermatology. 1999;113(3):364-368.
- Shah R, Reyes-Gordillo K, Cheng Y, et al. Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice. Oxidative Medicine and Cellular Longevity. 2018;2018:9630175.
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 e seu(sua) metabolites by UHPLC-Q-Exactive orbitrap MS/MS e seus(suas) screening by cicatrizacao de feridas activities in-vitro. Journal of Chromatography B. 2024;1235:124033.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta 4 acelera cicatrizacao de feridas. Journal of Investigative Dermatology. 1999;113(3):364-368.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomizado, controlado por placebo, Phase II ensaio clinico. Clinical Ophthalmology. 2015;9:877-884.
- Sosne G, Dunn SP, Kim C. Thymosin β4 Significantly Improves Signs and Symptoms of Severe Dry Eye in a Phase 2 Randomized Trial. Cornea. 2015;34(5):491-496.
- Bao W, Ballard VL, Needle S, et al. Cardioprotection by sistemico(a) dosing of thymosin beta four apos ischemic myocardial injury. Frontiers in Pharmacology. 2013;4:149.
- Treadwell T, Kleinman HK, Crockford D, et al. The regenerative peptide thymosin β4 acelera a taxa of dermal healing in preclinical modelo animals e em patients. Annals do(a) New York Academy of Sciences. 2012;1270:37-44.
- Nguyen J, Verma S, Vuong VT, et al. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Investigative Ophthalmology & Visual Science. 2025;66(14):31.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta 4 defined by ativo(a) sites in short peptide sequences. The FASEB Journal. 2010;24(7):2144-2151.
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500 in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012;1265:57-69.
- Kwok WH, Leung GN, Wan TS, et al. Doping control analysis of seven peptide hormones in horse plasma and urine by liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry. 2013;405:2653-2667.
- Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induz adult epicardial progenitor mobilization and neovascularizacao. Nature. 2007;445(7124):177-182.
- RegeneRx Biopharmaceuticals. Phase I Safety Trial for RGN-352: Injectable Thymosin Beta 4. 2009.
- Treadwell T, Kleinman HK, Crockford D, et al. The regenerative peptide thymosin β4 acelera dermal healing. Annals do(a) New York Academy of Sciences. 2012;1270:37-44.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.
